Evaluating new therapies in gastrointestinal stromal tumor using in vivo molecular optical imaging

References

• Goettsch WG, Bos SD, Breekveldt-Postma N, Casparie M, Herings RM, Hogendoorn PC. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer 2005; 41:2868 - 72; http://dx.doi.org/10.1016/j.ejca.2005.09.009; PMID: 16293410
   PubMed Web of Science ®Google Scholar
• Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, Blay JY, Leyvraz S, Stul M, Casali PG, et al, EORTC Soft Tissue and Bone Sarcoma Group, Italian Sarcoma Group, Australasian GastroIntestinal Trials Group. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42:1093 - 103; http://dx.doi.org/10.1016/j.ejca.2006.01.030; PMID: 16624552
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368:1329 - 38; http://dx.doi.org/10.1016/S0140-6736(06)69446-4; PMID: 17046465
   PubMed Web of Science ®Google Scholar
• FDA approves regorafenib (Stivarga) for GIST. Oncology (Williston Park) 2013; 27:164; PMID: 23687782
   PubMed Web of Science ®Google Scholar
• Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, et al, GRID study investigators. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381:295 - 302; http://dx.doi.org/10.1016/S0140-6736(12)61857-1; PMID: 23177515
   PubMed Web of Science ®Google Scholar
• Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25:1753 - 9; http://dx.doi.org/10.1200/JCO.2006.07.3049; PMID: 17470865
   PubMed Web of Science ®Google Scholar
• Henze J, Mühlenberg T, Simon S, Grabellus F, Rubin B, Taeger G, Schuler M, Treckmann J, Debiec-Rychter M, Taguchi T, et al. p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors. PLoS One 2012; 7:e37776; http://dx.doi.org/10.1371/journal.pone.0037776; PMID: 22662219
   PubMed Web of Science ®Google Scholar
• Gordon PM, Fisher DE. Role for the proapoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT-dependent gastrointestinal stromal tumor cell line. J Biol Chem 2010; 285:14109 - 14; http://dx.doi.org/10.1074/jbc.M109.078592; PMID: 20231287
   PubMed Web of Science ®Google Scholar
• Nakatani H, Araki K, Jin T, Kobayashi M, Sugimoto T, Akimori T, Namikawa T, Okamoto K, Nakano T, Okabayashi T, et al. STI571 (Glivec) induces cell death in the gastrointestinal stromal tumor cell line, GIST-T1, via endoplasmic reticulum stress response. Int J Mol Med 2006; 17:893 - 7; PMID: 16596277
   PubMed Web of Science ®Google Scholar
• Bauer S, Duensing A, Demetri GD, Fletcher JA. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene 2007; 26:7560 - 8; http://dx.doi.org/10.1038/sj.onc.1210558; PMID: 17546049
   PubMed Web of Science ®Google Scholar
• Vadakara J, von Mehren M. Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies. Hematol Oncol Clin North Am 2013; 27:905 - 20; http://dx.doi.org/10.1016/j.hoc.2013.07.007; PMID: 24093167
   PubMed Web of Science ®Google Scholar
• Pantaleo MA, Landuzzi L, Nicoletti G, Nanni C, Boschi S, Piazzi G, Santini D, Di Battista M, Castellucci P, Lodi F, et al. Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the gastrointestinal stromal tumors model. Clin Exp Med 2009; 9:199 - 205; PMID: 19225718
   PubMed Web of Science ®Google Scholar
• Pantaleo MA, Nicoletti G, Nanni C, Gnocchi C, Landuzzi L, Quarta C, Boschi S, Nannini M, Di Battista M, Castellucci P, et al. Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. J Exp Clin Cancer Res 2010; 29:173; PMID: 21192792
   PubMed Web of Science ®Google Scholar
• Revheim ME, Røe K, Bruland OS, Bach-Gansmo T, Skretting A, Seierstad T. Monitoring the effect of targeted therapies in a gastrointestinal stromal tumor xenograft using a clinical PET/CT. Mol Imaging Biol 2011; 13:1234 - 40; http://dx.doi.org/10.1007/s11307-010-0464-0; PMID: 21161686
   PubMed Web of Science ®Google Scholar
• Cullinane C, Dorow DS, Kansara M, Conus N, Binns D, Hicks RJ, Ashman LK, McArthur GA, Thomas DM. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. Cancer Res 2005; 65:9633 - 6; http://dx.doi.org/10.1158/0008-5472.CAN-05-2285; PMID: 16266981
   PubMed Web of Science ®Google Scholar
• Floris G, Wozniak A, Sciot R, Li H, Friedman L, Van Looy T, Wellens J, Vermaelen P, Deroose CM, Fletcher JA, et al. A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal. Clin Cancer Res 2013; 19:620 - 30; http://dx.doi.org/10.1158/1078-0432.CCR-12-2853; PMID: 23231951
   PubMed Web of Science ®Google Scholar
• Metildi CA, Tang CM, Kaushal S, Leonard SY, Magistri P, Tran Cao HS, Hoffman RM, Bouvet M, Sicklick JK. In Vivo Fluorescence Imaging of Gastrointestinal Stromal Tumors Using Fluorophore-Conjugated Anti-KIT Antibody. Annals of surgical oncology.
   Google Scholar
• Taguchi T, Sonobe H, Toyonaga S, Yamasaki I, Shuin T, Takano A, Araki K, Akimaru K, Yuri K. Conventional and molecular cytogenetic characterization of a new human cell line, GIST-T1, established from gastrointestinal stromal tumor. Lab Invest 2002; 82:663 - 5; http://dx.doi.org/10.1038/labinvest.3780461; PMID: 12004007
   PubMed Web of Science ®Google Scholar
• Kossodo S, Pickarski M, Lin SA, Gleason A, Gaspar R, Buono C, Ho G, Blusztajn A, Cuneo G, Zhang J, et al. Dual in vivo quantification of integrin-targeted and protease-activated agents in cancer using fluorescence molecular tomography (FMT). Mol Imaging Biol 2010; 12:488 - 99; http://dx.doi.org/10.1007/s11307-009-0279-z; PMID: 19960268
   PubMed Web of Science ®Google Scholar
• Smith BA, Akers WJ, Leevy WM, Lampkins AJ, Xiao S, Wolter W, Suckow MA, Achilefu S, Smith BD. Optical imaging of mammary and prostate tumors in living animals using a synthetic near infrared zinc(II)-dipicolylamine probe for anionic cell surfaces. J Am Chem Soc 2010; 132:67 - 9; http://dx.doi.org/10.1021/ja908467y; PMID: 20014845
   PubMed Web of Science ®Google Scholar
• Hanshaw RG, Smith BD. New reagents for phosphatidylserine recognition and detection of apoptosis. Bioorg Med Chem 2005; 13:5035 - 42; http://dx.doi.org/10.1016/j.bmc.2005.04.071; PMID: 15914007
   PubMed Web of Science ®Google Scholar
• Maxwell D, Chang Q, Zhang X, Barnett EM, Piwnica-Worms D. An improved cell-penetrating, caspase-activatable, near-infrared fluorescent peptide for apoptosis imaging. Bioconjug Chem 2009; 20:702 - 9; http://dx.doi.org/10.1021/bc800516n; PMID: 19331388
   PubMed Web of Science ®Google Scholar
• Johnson JR, Kocher B, Barnett EM, Marasa J, Piwnica-Worms D. Caspase-activated cell-penetrating peptides reveal temporal coupling between endosomal release and apoptosis in an RGC-5 cell model. Bioconjug Chem 2012; 23:1783 - 93; http://dx.doi.org/10.1021/bc300036z; PMID: 22900707
   PubMed Web of Science ®Google Scholar
• Barnett EM, Zhang X, Maxwell D, Chang Q, Piwnica-Worms D. Single-cell imaging of retinal ganglion cell apoptosis with a cell-penetrating, activatable peptide probe in an in vivo glaucoma model. Proc Natl Acad Sci U S A 2009; 106:9391 - 6; http://dx.doi.org/10.1073/pnas.0812884106; PMID: 19458250
   PubMed Web of Science ®Google Scholar